Performance of UMSARS evaluated

Researchers have identified potential baseline and ceiling effects with use of the Unified Multiple System Atrophy Rating Scale (UMSARS), which could have important implications for clinical trial planning.

Dr Miguel Pérez from the NYU School of Medicine, in New York, USA, said previous studies have shown a wide variability in disease progression as measured by UMSARS: reported 1-year rates have ranged from 3.9-6.5 with UMSARS-I and from 3.6-8.2 with UMSARS-II.

Dr Pérez and colleagues hypothesized that this variability could be due to differences in severity at enrollment and a potential ceiling effect in the rating scale: patients in more advanced stages may appear to worsen less.

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.